Related Experiment Video

Updated: Oct 2, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway

Hong Lin1, Balanehru Subramanian, Alex Nakeff

  • 1Division of Hematology-Oncology, 516 Hudson Webber Cancer Research Center, Barbara Ann Karmanos Cancer Institute, 4100 John R. Detroit, MI 48201, USA.

Cancer Chemotherapy and Pharmacology
|March 27, 2002
PubMed
Abstract

Insights

XK469 is a novel antitumor agent that halts leukemia cell growth by inhibiting the MEK/MAPK pathway. This agent shows antiproliferative effects with minimal cytotoxicity, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • XK469 is a novel antitumor agent with demonstrated activity against various tumors, including drug-resistant types.
  • Previous research indicated XK469 possesses antiproliferative properties with low cytotoxic effects in human H116 tumor cells.

Purpose of the Study:

  • To elucidate the specific signaling pathways responsible for the antiproliferative activity of XK469.
  • To investigate the mechanism of action of XK469 in human leukemia cells.

Main Methods:

  • Utilized human U-937 leukemia cells in culture to assess XK469's antiproliferative effects.
  • Employed flow cytometry for cell cycle arrest analysis and immunoblotting to detect MEK/MAPK phosphorylation.
  • Analyzed the impact of XK469 on cell cycle progression and key signaling proteins.

Main Results:

  • XK469 induced cell cycle arrest at the G(2)/M phase in U-937 cells, with minimal cytotoxic or apoptotic effects compared to conventional agents.
  • XK469 potently inhibited the phosphorylation and activation of MEK (Mitogen-activated protein kinase kinase) and its downstream target MAPK (Mitogen-activated protein kinase).
  • The antiproliferative effect correlated with the accumulation of cyclins B1 and A, a consequence of G(2)/M arrest.

Conclusions:

  • The antiproliferative effects of XK469 in U-937 human leukemia cells are mediated through the inhibition of the MEK/MAPK signaling pathway.
  • XK469 represents a promising therapeutic agent due to its targeted antiproliferative action without significant cytotoxicity.

More Related Videos

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...